Journal
EUROPEAN JOURNAL OF RADIOLOGY
Volume 81, Issue 11, Pages 3551-3556Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ejrad.2012.03.016
Keywords
Positron emission tomography (PET); Intensity-modulated radiotherapy (IMRT); Ovarian cancer; Recurrence
Funding
- National Natural Science Foundation of China [30901713]
- Shandong Key Scientific and Technological Project [2010GSF10233, 2009GG10002010]
- Shandong Natural Science Foundation [BS2010YY065]
Ask authors/readers for more resources
Objective: This study was undertaken to evaluate the clinical contribution of positron emission tomography using F-18-fluorodeoxyglucose and integrated computer tomography (FDG-PET/CT) guided intensity-modulated radiotherapy (IMRT) for treatment of recurrent ovarian cancer. Materials and methods: Fifty-eight patients with recurrent ovarian cancer from 2003 to 2008 were retrospectively studied. In these patients, 28 received PET/CT guided IMRT (PET/CT-IMRT group), and 30 received CT guided IMRT (CT-IMRT group). Treatment plans, tumor response, toxicities and survival were evaluated. Results: Changes in GTV delineation were found in 10 (35.7%) patients based on PET-CT information compared with CT data, due to the incorporation of additional lymph node metastases and extension of the metastasis tumor. PET/CT guided IMRT improved tumor response compared to CT-IMRT group (CR: 64.3% vs. 46.7%, P = 0.021; PR: 25.0% vs. 13.3%, P = 0.036). The 3-year overall survival was significantly higher in the PET-CT/IMRT group than control (34.1% vs. 13.2%, P = 0.014). Conclusions: PET/CT guided IMRT in recurrent ovarian cancer patients improved the delineation of GTV and reduce the likelihood of geographic misses and therefore improve the clinical outcome. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available